Last $8.04 USD
Change Today +0.04 / 0.50%
Volume 80.8K
AKAO On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 09/29/14 All times are local (Market data is delayed by at least 15 minutes).

achaogen inc (AKAO) Snapshot

Open
$7.86
Previous Close
$8.00
Day High
$8.05
Day Low
$7.72
52 Week High
03/24/14 - $19.69
52 Week Low
09/29/14 - $7.72
Market Cap
142.4M
Average Volume 10 Days
63.0K
EPS TTM
--
Shares Outstanding
17.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACHAOGEN INC (AKAO)

Related News

No related news articles were found.

achaogen inc (AKAO) Related Businessweek News

No Related Businessweek News Found

achaogen inc (AKAO) Details

Achaogen, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant gram-negative infections. The company is principally developing plazomicin, which has completed Phase II clinical trials for the treatment of bacterial infections due to multi-drug resistant Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. It is also involved in the research and development of antipseudomonal programs that target infections caused by Pseudomonas aeruginosa. Achaogen, Inc. was incorporated in 2002 and is headquartered in South San Francisco, California.

43 Employees
Last Reported Date: 08/11/14
Founded in 2002

achaogen inc (AKAO) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $367.2K
Senior Vice President of Development Operatio...
Total Annual Compensation: $285.6K
Vice President of Finance and Corporate Devel...
Total Annual Compensation: $248.1K
Vice President of Regulatory Affairs
Total Annual Compensation: $279.8K
Compensation as of Fiscal Year 2013.

achaogen inc (AKAO) Key Developments

Achaogen, Inc. Announces First Patient Enrollment in Phase 3 Clinical Trial of Plazomicin to Treat Infections Caused by Carbapenem-resistant Enterobacteriaceae

Achaogen, Inc. announced that the first patient has been enrolled in a Phase 3 clinical trial of plazomicin to treat infections caused by carbapenem-resistant Enterobacteriaceae (CRE). The Phase 3 clinical trial is designed to demonstrate the superiority, in terms of mortality at 28 days, of a plazomicin-based regimen compared with a colistin-based regimen in the treatment of patients with bloodstream infections or nosocomial pneumonia due to CRE. The trial is being conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration. Achaogen's plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority (BARDA) for up to $103.8 million. The need for new antibiotics to treat CRE is particularly acute, as these bacteria are commonly multi-drug resistant-that is, they are insensitive to nearly all antibiotics commonly used to treat gram-negative infections, including carbapenems, cephalosporins, beta-lactam/beta-lactamase inhibitor combinations, fluoroquinolones, and currently-marketed aminoglycosides. Resistance to carbapenems has been highlighted as a particular concern because carbapenems are one of the last lines of defense against antibiotic-resistant gram-negative infections. Most CRE express enzymes called carbapenemases, which break down the carbapenem antibiotic molecule before it can kill the bacteria. Due to the lack of effective therapies, CRE infections are associated with significant mortality, with up to 50% mortality observed in patients with bloodstream infections.

Achaogen, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Achaogen, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported contract revenue of $5,203,000 against $4,498,000 a year ago. Loss from operations was $3,338,000 against $4,206,000 a year ago. Net loss and comprehensive loss was $3,555,000 or $0.20 per basic and diluted share against $4,310,000 or $11.08 per basic and diluted share a year ago. For the six months, the company reported contract revenue of $11,191,000 against $8,031,000 a year ago. Loss from operations was $6,572,000 against $7,488,000 a year ago. Net loss and comprehensive loss was $7,010,000 or $0.66 per basic and diluted share against $8,063,000 or $21.10 per basic and diluted share a year ago.

Achaogen, Inc. Appoints Dr. Ian Friedland as Chief Medical Officer

Achaogen, Inc. announced the appointment of Ian Friedland, M.D. as its Chief Medical Officer. In this position, Ian's responsibilities will include leadership of the pivotal Phase 3 trial for plazomicin, Achaogen's lead product for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Dr. Friedland has spent sixteen years in drug development at emerging therapeutic companies and large pharmaceutical companies. Prior to joining Achaogen, Dr. Friedland served as Vice President, Clinical Development at Cubist Pharmaceuticals.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AKAO:US $8.04 USD +0.04

AKAO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AKAO.
View Industry Companies
 

Industry Analysis

AKAO

Industry Average

Valuation AKAO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.5x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACHAOGEN INC, please visit www.achaogen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.